Orgenesis Inc. (ORGS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 8 | 36 | 36 | 1 | - | - | - | - |
| Operating profit | $m | -54 | - | ||||||
| Net profit | $m | -96 | -18 | -15 | -55 | - | - | - | - |
| EPS reported | $ | -1.91 | - | ||||||
| Operating cashflow per share | $ | -0.51 | - | ||||||
| Capex per share | $ | 0.07 | - | ||||||
| FCF per share | $ | -0.58 | - | ||||||
| Free cash flow | $m | -17 | - | ||||||
| Net debt | $m | 21 | - | ||||||
| Book value equity | $m | -21 | - | ||||||
| Book value per share | $ | -0.72 | - | ||||||
| Number of shares | m | 29.01 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -6.91 | - | ||||||
| P/S LTM | x | 273.66 | - | ||||||
| P/FCF LTM | x | -8.57 | - | ||||||
| EV/EBITDA LTM | x | -2.75 | - | ||||||
| EV/Sales LTM | x | 314.76 | - | ||||||
| Earnings Yield LTM | % | -38.17% | - | ||||||
| FCF Yield | % | -11.67% | - | ||||||
| Quality | |||||||||
| ROE | % | +263.84% | - | ||||||
| ROIC | % | -31.57% | - | ||||||
| Operating margin | % | -101.20% | - | ||||||
| Gross margin | % | -10.80% | - | ||||||
| FCF/Sales | % | -3194.9% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -98.53% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -0.75 | - | ||||||
| Net Debt/EBITDA | x | -0.36 | - | ||||||
| EBIT/Net interest | x | -24.75 | - | ||||||
| Net debt/market cap | % | +15.37% | - | ||||||
| Net debt/Equity | x | -1.02 | - | ||||||
| Gross debt/equity | x | -1.08 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free